Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BACE Inhibitors Worsen Cognition in Patients with Prodromal Alzheimer’s Disease

Key clinical point: Verubecestat and atabecestat fail in clinical trials for preclinical Alzheimer’s disease.

Major finding: BACE inhibitors worsened cognition in patients with prodromal Alzheimer’s disease.

Study details: The two studies randomized patients to varying doses of verubecestat and atabecestat.

Disclosures: Merck & Co. sponsored the verubecestat study. Janssen sponsored the atabecestat study.

Citation:

Egan MF et al. N Engl J Med. 2019 Apr 11;380:1408-20.